A B S T R A~ The Committee on Risk Assessment Methodology of the Board on Environmental Studies and Toxicology of the National Academy of Sciences has considered issues related to the use of the maximum tolerated dose (MTD) in carcinogenesis bioassays and of 2-stage models of carcinogenesis. In each case, the goal has been to consider whether sufficient information is available to lead to a change in current methodology used by regulatory agencies in assessing risk. The majority of the committee favored retention of the MTD but recommended that lower doses also be used for cancer bioassays and, if the results are positive, performance of additional mechanistic studies aimed at improved extrapolation to environmentally relevant concentrations. The minority recommended that additional preliminary studies be done in order to obtain information about the highest dose relevant to extrapolation to humans for use in the cancer bioassay. Two-stage carcinogenesis models were found to be an excellent approach to increase understanding but required an extensive toxicological data base beyond that available for most chemicals. These deliberations have highlighted the value of increased understanding of the basic mechanisms of action of potential cancer-causing chemicals in order to advance the methodology of risk assessment.
INTRODUCTION
The Committee on Risk Assessment Methodology (CRAM) was constituted by the Board on Environmental Studies and Toxicology, National Academy of Sciences, National Research Council, to review various aspects ofthe methodology of risk assessment. This relatively new and rapidly developing scientific area has increasingly played a role in the decision-making processes of various federal agencies. This has led to significant attention being placed on the methodology involved in the assessment of risk by the regulated community as weil as the public, environmental, and labor organizations a,nd the regulators.
The National Academy of Sciences has been relatively active in the area ofrisk assessment. Its Redbook (9) was a major impetus toward the increasing use of a formal methodology of risk assessment in regulatory decision-making. The risk assessment paradigm has since been used by a number of academy committees evaluating aspects of the effects of chemical and physical agents on humans and the environment.
In some ways, the course taken by CRAM represented a departure from usual National Academy of Science committee efforts. An innovative approach was the constitution of a federal liaison group (FLG) . The FLG worked with CRAM on the choice of topics, on the formulation of the charge within a given topic, and, where indicated, in the development of a workshop that usually preceded committee deliberations. The FLG consisted of representatives, usually those charged with doing risk assessment, from a variety of federal agencies including the Environmental Protection Agency, the Food and Drug Administration, the Department of Agriculture, the Consumer Product Safety Commission, the Department of Defense, NIOSH, ATSDR, and other public health-related agencies. H~~, ,~~~~, Once the problem was formulated and the workshop the FLG members did not CRAM working groups set up to consider specific topics. These working groups were made up of CRAM members. They were responsible for the drafting of a consensus document, but final decisions were made by the entire committee. In addition to the workshop presentations, there were commissioned reports and extensive committee deliberations that formed the basis for the eventual report.
The first 2 topics chosen for committee efforts were the maximum tolerated dose (MTD) in animal bioassays for carcinogenicity and the 2-stage model of carcinogenesis. I will briefly present the 'committee's findings in this article. These 2 reports, along with the third committee report on ecological risk assessment, were released by the National Research Council in early 1993 in a book entitled Issiies in Risk Assessriieiit (10) .
MTD
The use of the MTD for cancer risk assessment has been an area of increasing controversy. The choice by CRAM of this topic preceded the recent enhancement in this controversy caused by the publication of an important critique in Science by Ames and Gold (1) . This publication and the associated national publicity occurred just a few days before the committee's workshop on the subject.
The use of the MTD in long-term animal studies has been a part of the bioassay of chemicals for possible carcinogenicity for over 20 yr (6). The MTD operationally is usually the highest tested dose. It is commonly derived from preliminary studies in which a relatively large range of doses is chosen and given to small groups of laboratory animals for 90 days. The MTD chosen for long-term study in the cancer bioassay is the highest dose that is not observed to produce overt toxicity and has little or no effect on the growth of the animal.
The rationale for the use of the MTD includes the fact that regulatory agencies have been given mandates to protect the public against cancer risks that are relatively stringent (e.g., 1 in 100,000, 1 in 1,000,000). The number of animals required to evaluate whether or not environmentally relevant concentrations of compounds might possibly be responsible for such low-level risk is well beyond the capabilities of the bioassay laboratories. The crux of the MTD approach is the assumption that by extrapolating downward from higher doses, it is possible to estimate cancer risk at lower doses and thereby use fewer laboratory animals for the cancer assay. For any fixed number of animals, the higher the dose, the greater the sensitivity to detect lowlevel cancer risk.
Criticism of the MTD has occurred for as long as it has been in use. Its limitations are well recognized. A central problem is that any alteration of normal physiology at high dqse may alter the animal's responsiveness in a manner that is not meaningful for the lower doses to which extrapolation will occur. For example, a metabolic step necessary for either detoxification or for the formation of a carcinogen from the parent compound may become saturated at higher doses. This would affect quantitative extrapolation. Perhaps more important is the possibility that problems with using the MTD may cause an erroncous qualitative determination of whether or not a compound is a carcinogen in the test species. For example, Ames and Gold (1) and Cohen and Ellwein (2, 3) as well as others have focused on whether at high doses one might get increased cell turnover without overt toxicity in a target organ. This increased cell turnover hypothetically could be the basis for developing cancer, at the high dose, that would not have occurred at all in the lower doses that are of environmental concern. The possibility of alterations in hormonal balance occumng only at higher doses has also been suggested.
The committee noted many advantages to the MTD. These include the.fact that the current bioassay using the MTD provides an operational definition of a noncarcinogen. Target organs are identified, providing guidance for epidemiological studies in humans. The standard-bioassay using the MTD also provides a basis for interspecies comparison and other comparative information on the carcinogenic potency of high doses including differences in sensitivity between the sexes and between different strains and species of rodents, which are the test animals commonly used.
There was general agreement about many of the problems concerning the MTD. In particular, it was agreed that chemical compounds might be identified as carcinogenic at high doses through mechanisms that do not operate at lower doses. It was also clearly recognized that studies solely at the MTD provide little information related to mechanism.
A major impetus for CRAM'S choice of the MTD as a topic was studies showing a statistically significant relationship in measures of carcinogenic potency such as the TDSo (the dose causing tumors in 50% of test animals) with the MTD and other measures of toxicity (4, 5). The high correlation of the MTD with cancer potency among the many chemicals that have been subjected to bioassay suggests that carcinogenicity is somehow inherently related to other toxic effects produced by a chemical. A counter-argument to this relationship is that it is artifactually based on some aspect of the bioassay design and the statistical methods used to estimate GOLDSTEIN TOXICOLOGIC PATHOLOGY potency and to estimate the reported correlations. The committee's analysis led to the conclusion that this high correlation is not wholly due to statistical or mathematical artifacts but, for those compounds that are carcinogenic, do point to an underlying relationship between measures ofgeneral toxicity, such as the MTD, and measures of cancer potency. The committee suggested that, because of this relationship, a preliminary estimate of the carcinogenic potency, if the compound turns out to be a carcinogen, could be derived from its MTD. This could be useful in setting priorities for testing and in estimating risk when the bioassay has not yet been done. The committee also concluded that the MTD is of value in limiting false-negatives in the cancer bioassay and also can be a useful approach in detecting target organs for noncancer toxicity.
In response to its charge to make recommendations concerning methodology to be used by regulatory agencies, the committee considered 4 options: (a) retain the current bioassay procedure, possibly with the addition of doses below the MTD; (b) use a high dose that is an arbitrary fraction of the usual MTD (e.g., 50% of the MTD); (c) develop a new definition of the MTD, basing it on studies of physiological effects at different doses; or (d) use MTD testing as 1 part of an overall testing strategy that not only attempts to separate carcinogens from noncarcinogens but also provides additional information useful for determining relevance to humans.
Despite agreement on many of the preceding issues, the committee could not come to a full consensus on these 4 options. A majority preferred the fourth option, recommending that the MTD be retained as one of the doses in use in carcinogenesis bioassays. Other lower doses, perhaps down to b3 or an even lower fraction ofthe MTD, would be chosen based on metabolic factors or other physiological parameters related to the particular chemical. If the results are positive for cancer, it was recommended that additional studies should focus on reducing uncertainties in the prediction of human response and in human risk assessment by addressing mechanisms of cancer induction, toxicokinetics, and physiological responses.
The minority of the committee supported the third option, asking for a modification of the dose selection procedures for a carcinogenicity bioassay. Dose selection would be done by a panel of experts on the basis of evaluation of subchronic studies. The highest dose to be used would be that which was believed to provide results relevant to humans, not just simply the highest dose that does not cause overt toxicity. The core of basic information would be gathered prior to initiation ofthe bioassay. The data obtained would include how different doses, includ-ing repeated exposures, affect various processes that are responsible for homeostasis, hormonal balance, cell proliferation, and the metabolism of a test chemical.
Although somewhat of a simplification, the major difference between the majority and minority views could be characterized as whether or not toxicological science has sufficiently advanced so that various biochemical and physiological parameters can be routinely used to choose in advance the proper dose for long-term bioassays. I think it is fair to say that the majority strongly hope that the minority eventually will be right, that the state of basic science will have advanced so that there is sufficient understanding of the relevant parameters related to human carcinogenicity that permits physiologicalbased animal studies to be used with reasonable assurance to pick the highest test dose. In essence, the majority did not believe that the state of scientific knowledge is sufficiently advanced at this time to recommend a change.
THE 2-STAGE MODEL OF CARCINOGENESIS The basic conceptual approach to understanding chemical carcinogenesis began with the observation that in theory a single mutation ofa normal somatic cell could produce a progenitor cancer cell from which the cancer clone was derived. As cancer biology has become more sophisticated, it has become clear that for the most part human cancers are multistage processes, something that has long been evident to clinicians dealing with common tumors such as colon cancer and cancer of the cervix. Some of the more exciting advances in molecular biology as applied to human cancer tissue have been findings that for certain tumors there are at least 6 steps between the initial mutation and the eventual metastatic tumor; with many if not all of these steps being marked by mutation of a specific oncogene or suppressor gene (1 1).
In recent years there has also been an increase in the sophistication of the mathematical models that have been developed to assess cancer risk. In particular, much effort has gone into a model based on a 2-stage paradigm for cancer causation (7, 8) . The paradigm is based particularly on the relationship between tumor incidence and age, which suggests that there are at least 2 critical cellular changes necessary for the development of many cancers. The 2-stage model can then be considered to be a first and highly necessary step along the way to incor-.porate all of the biological information now being developed related to the multiple stages of cancer.
CRAM chose as its second topic the feasibility of the use by regulatory agencies of 2-stage models in risk assessment. The committee notes that, in gen-eral, 2 approaches have been used for fitting 2-stage models to data. In one approach, trial values of parameters are specified as is simulation of the subsequent tumor response. Values are then changed until there is close conformity with the data. In a second approach, standard statistical data fitting methods, such as maximum likelihood estimates, are used. The committee recognizes that the first approach can be useful in situations such as exploratory data analysis. However, whenever possible the committee suggests that formal statistical methodology should be used to estimate the values of parameters, assess goodness of fit, calculate statistical confidence intervals, and determine the extent to which there is consistency of the models with other mathematical representations and ranges of risk. A central feature in the applying the 2-stage model to bioassay data is the reliance on a basic understanding of mechanism and a requirement for ample toxicological data. To evaluate how robust these models are, the committee explored several applications of the 2-stage model to carcinogens with different mechanisms of actions and with different quantities of available data in rodent studies. The committee found that in each case numerous assumptions were necessaty to apply the model, including assumptions about appropriate target cells, time dependence, mechanisms of action, and the shape of the dose-response relationship. Thus, extensive data would be needed to reduce the current uncertainty and assumptions, data that, with few exceptions, are not available. The committee found that when different forms ofthe model are consistent with a particular data set, the estimates of risk can differ by orders of magnitude. Thus, even with a large amount of data, it is still difficult using the 2-stage model to accurately predict risk in the range of 1 in a million, even if the mechanisms of actions are also well understood.
The Committee concludes that one of the strengths of the 2-stage model is its ability to bring information to bear from knowledge about intermediate steps in carcinogenesis. Unfortunately, it is currently difficult to characterize these steps. Accordingly, before the 2-stage model can be routinely incorporated into cancer risk assessment, additional bioassay data will need to be generated. The committee recommends that at present the 2-stage model should be used primarily to increase understanding, for which it is a highly valuable tool. When adequate data is available, it should be used in risk assessment along with other models to add perspective and understanding. In rare instances, when there is both adequate data and mechanistic understanding, it should be possible to use the 2-stage model as a basis for decision-making.
